A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer

被引:1
|
作者
Bolton, Katherine A. [1 ,2 ]
Avery-Kiejda, Kelly A. [1 ,2 ]
Holliday, Elizabeth G. [3 ,4 ]
Attia, John [3 ,4 ]
Bowden, Nikola A. [1 ,2 ]
Scott, Rodney J. [1 ,2 ,5 ,6 ]
机构
[1] Hunter Med Res Inst, Ctr Bioinformat Biomarker Discovery & Informat Ba, Newcastle, NSW, Australia
[2] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Prior Res Ctr Canc, Newcastle, NSW, Australia
[3] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia
[4] Hunter Med Res Inst, Clin Res Design IT & Stat Support Unit, Newcastle, NSW, Australia
[5] John Hunter Hosp, Pathol North, Mol Med, Newcastle, NSW, Australia
[6] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Discipline Med Genet, Univ Dr, Newcastle, NSW, Australia
基金
英国医学研究理事会;
关键词
IGF1; gene; short tandem repeat; promoter region; endometrial cancer; breast cancer; GROWTH-FACTOR-I; FACTOR-RECEPTOR GENE; BODY-MASS INDEX; BREAST-CANCER; CA REPEAT; SEQUENCE REPEAT; TANDEM REPEATS; OBESITY; DNA; SUSCEPTIBILITY;
D O I
10.1530/EC-16-0003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to the lack of high-throughput genetic assays for tandem repeats, there is a paucity of knowledge about the role they may play in disease. A polymorphic CA repeat in the promoter region of the insulin-like growth factor 1 gene (IGF1) has been studied extensively over the past 10 years for association with the risk of developing breast cancer, among other cancers, with variable results. The aim of this study was to determine if this CA repeat is associated with the risk of developing breast cancer and endometrial cancer. Using a case-control design, we analysed the length of this CA repeat in a series of breast cancer and endometrial cancer cases and compared this with a control population. Our results showed an association when both alleles were considered in breast and endometrial cancers (P = 0.029 and 0.011, respectively), but this did not pass our corrected threshold for significance due to multiple testing. When the allele lengths were analysed categorically against the most common allele length of 19 CA repeats, an association was observed with the risk of endometrial cancer due to a reduction in the number of long alleles (P = 0.013). This was confirmed in an analysis of the long alleles separately for endometrial cancer risk (P = 0.0012). Our study found no association between the length of this polymorphic CA repeat and breast cancer risk. The significant association observed between the CA repeat length and the risk of developing endometrial cancer has not been previously reported.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 50 条
  • [21] IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer
    Al-Zahrani, A
    Sandhu, MS
    Luben, RN
    Thompson, D
    Baynes, C
    Pooley, KA
    Luccarini, C
    Munday, H
    Perkins, B
    Smith, P
    Pharoah, PDP
    Wareham, NJ
    Easton, DF
    Ponder, BAJ
    Dunning, AM
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (01) : 1 - 10
  • [22] Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer
    Johansson, Mattias
    Mckay, James D.
    Stattin, Par
    Canzian, Federico
    Boillot, Catherine
    Wiklund, Fredrik
    Adami, Hans-Olov
    Balter, Katarina
    Gronberg, Henrik
    Kaaks, Rudolf
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (03) : 539 - 542
  • [23] Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort
    Cheng, I
    Stram, DO
    Penney, KL
    Pike, M
    Le Marchand, L
    Kolonel, LN
    Hirschhorn, J
    Altshuler, D
    Henderson, BE
    Freedman, ML
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (02) : 123 - 134
  • [24] DO THE DIFFERENT NUMBER OF CA REPEATS IN P1 PROMOTER OF IGF1 GENE MAY INFLUENCED PLASMA IGF1 LEVELS?
    Burchardt, P.
    Gozdzicka-Jozefiak, A.
    Nowak, W.
    Siminiak, T.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 131 - 131
  • [25] GH and IGF1 in cancer therapy resistance
    Basu, Reetobrata
    Kopchick, John J.
    [J]. ENDOCRINE-RELATED CANCER, 2023, 30 (09)
  • [26] Targeting the IGF1 axis in cancer proliferation
    Bruchim, Ilan
    Attias, Zohar
    Werner, Haim
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (10) : 1179 - 1192
  • [27] IGF1 (CA)19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in black and white men
    Schildkraut, JM
    Demark-Wahnefried, W
    Wenham, RM
    Grubber, J
    Jeffreys, AS
    Grambow, SC
    Marks, JR
    Moorman, PG
    Hoyo, C
    Ali, S
    Walther, PJ
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) : 403 - 408
  • [28] IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer
    Reeves, Stuart G.
    Rich, Dominique
    Meldrum, Cliff J.
    Colyvas, Kim
    Kurzawski, Grzegorz
    Suchy, Janina
    Lubinski, Jan
    Scott, Rodney J.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (06) : 1339 - 1343
  • [29] Response to the letter to editor "The association between IGF1 CA repeat polymorphisms and breast cancer risk: appraisal of a recent meta-analysis''
    Huang, Qiang
    Wang, Chen
    Qiu, LuJun
    Shao, Feng
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (03) : 915 - 915
  • [30] Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor
    De Santi, Mauro
    Annibalini, Giosue
    Barbieri, Elena
    Villarini, Anna
    Vallorani, Luciana
    Contarelli, Serena
    Berrino, Franco
    Stocchi, Vilberto
    Brandi, Giorgio
    [J]. CELLULAR ONCOLOGY, 2016, 39 (02) : 149 - 159